Success Metrics

Active Trials

2(50%)

Phase Distribution

Ph phase_1

50%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Recruiting2

Enrolling by invitation1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 12 (66.7%)

Phase 31 (33.3%)

Trials by Status

enrolling_by_invitation125%

not_yet_recruiting125%

recruiting250%

Recent Activity

2 active trials

Showing 4 of 4

not_yet_recruitingphase_1

Study Of KITE-753 in R/R B-Cell ALL

NCT07674823

recruitingphase_3

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797

recruitingphase_1

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803

enrolling_by_invitation

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

NCT05041309

Clinical Trials (4)

Showing 4 of 4 trials

NCT07674823Phase 1

Study Of KITE-753 in R/R B-Cell ALL

Not Yet Recruiting

NCT07479797Phase 3

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Recruiting

NCT04989803Phase 1

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Recruiting

NCT05041309

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling By Invitation

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4